Skip to content

Study · Animal study (in vivo) · mouse · 2000

3 results

Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity.

Veinbergs I, Mante M, Mallory M, Masliah E

Journal of neural transmission. Supplementum1 Jan 2000Cited by 34 (Europe PMC)

PMID10961439 (opens in a new tab)DOI10.1007/978-3-7091-6781-6_29 (opens in a new tab)PepBankPUB-10961439
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, Cerebrolysin pretreatment protected water maze performance against kainic acid lesions.

    In plain wordsIn mice, Cerebrolysin pretreatment protected water maze performance against kainic acid damage.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseWater maze performance with pretreatment
    Study

    mousen: not reported in source

    Kainic acid excitotoxicity
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Behavioral testing in the water maze and assessment of neuronal structure by laser scanning confocal microscopy showed a significant protection against KA lesions in mice pretreated with Cerebrolysin.
    1 context sentence
    Summary · context
    In the first set of experiments, mice received intraperitoneal KA injections followed by Cerebrolysin administration, while in the second, mice were pretreated with Cerebrolysin for 4 weeks and then challenged with KA.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, Cerebrolysin pretreatment protected neuronal structure against kainic acid lesions.

    In plain wordsIn mice, Cerebrolysin pretreatment protected nerve cell structure against kainic acid damage.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseNeuronal structure with pretreatment
    Study

    mousen: not reported in source

    Kainic acid excitotoxicity
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Behavioral testing in the water maze and assessment of neuronal structure by laser scanning confocal microscopy showed a significant protection against KA lesions in mice pretreated with Cerebrolysin.
    1 context sentence
    Summary · context
    In the first set of experiments, mice received intraperitoneal KA injections followed by Cerebrolysin administration, while in the second, mice were pretreated with Cerebrolysin for 4 weeks and then challenged with KA.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, Cerebrolysin treatment after kainic acid injections did not produce significant improvement.

    In plain wordsIn mice, Cerebrolysin after kainic acid injections did not produce significant improvement.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeImprovement after kainic acid injections
    Study

    mousen: not reported in source

    Kainic acid excitotoxicity
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, mice that received Cerebrolysin after KA injections did not show significant improvement.
    1 context sentence
    Summary · context
    In the first set of experiments, mice received intraperitoneal KA injections followed by Cerebrolysin administration, while in the second, mice were pretreated with Cerebrolysin for 4 weeks and then challenged with KA.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT04830943

Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia

Assiut Universityn = 2501 Aug 2020 to 30 Oct 2022

Covid19 Related Anosmia and Aguesia

Trial pageClinicalTrials.govUpdated 3 Jan 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.